ClinicalTrials.gg
CompletedNCT04305405TATEUpdated May 18, 2023Results posted

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

A Phase 3 interventional study of Benralizumab in Severe Uncontrolled Asthma, sponsored by AstraZeneca. Completed at 15 sites in 2 countries. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by AstraZeneca · Phase 3, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
6 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
34th of 39
30 · median 128
Started
2019
with 4 others
Phase 3
20 of 39
1 open now
Registered
31st of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 34th largest by enrollment, is one of 5 that started in 2019, is one of 20 in phase 3, and was the 31st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 6 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

This study will evaluate the PK, PD and long-term safety of Benralizumab administered subcutaneously in 30 children aged 6 to 11 years with severe eosinophilic asthma. Up to an additional 3 Japanese patients aged 12 to 14 years will be enrolled to meet local regulatory requirements.

03

Conditions studied

  • Severe Uncontrolled Asthma

Browse trials for

Keywords

  • Pediatric
  • PK
  • severe asthma
04

Who can participate

Ages eligible
6 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the exclusion criteria apply:

  1. Parent(s)/guardian are able to give written prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. If applicable, the participant must be able and willing to give assent to take part in the study according to the local requirement.
  2. Patient must be 6 to 11 years of age inclusive (6 to 14 years of age inclusive in Japan), at the time of signing the ICF.
  3. Diagnosis of severe asthma, defined by the regional guidelines for at least 12 months prior to Visit 1.
  4. A previously confirmed history of two or more exacerbations requiring treatment with systemic and/or hospitalization in the 12 months prior to Visit 1.
  5. Peripheral blood eosinophil count of ≥ 150 cells / µL at Visit 1.
  6. A well-documented requirement for regular treatment with ICS: eg. total daily dose equivalent to ≥ 250 µg fluticasone propionate, in the 12 months prior to Visit 1, with or without maintenance oral corticosteroids.
  7. Current treatment with at least 1 additional controller medication, such as inhaled LABA, leukotriene receptor antagonist, long acting anti-muscarinic agent, or theophylline, since at least 3 months prior to Visit 1.
  8. Pre-bronchodilator ≤ 110% predicted normal, or, FEV1/Forced Vital Capacity (FVC) ratio ≤ 0.8.
  9. Body weight ≥15 kg.
  10. Male or female
  11. Females of (FOCBP) who are sexually active, as judged by the investigator, must commit to consistent and correct use of an acceptable method of for the duration of the study and for 4 months after the last dose of IP.

Exclusion criteria

Exclusion Criteria:

Patients are eligible to be included in the study only if all of the inclusion criteria and none of the exclusion criteria apply:

  1. Any history of life-threatening asthma (eg, requiring intubation).
  2. pulmonary disease other than asthma such as active lung infection, bronchiectasis, pulmonary fibrosis, cystic fibrosis, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia.
  3. Previous diagnosis of pulmonary or systematic disease, other than asthma, that is associated with elevated peripheral eosinophil counts such as allergic bronchopulmonary aspergillosis/mycosis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), and hypereosinophilic syndrome.
  4. Ever been diagnosed with malignant disease.
  5. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, immunological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

    1. Affect the safety of the patient throughout the study.
    2. Influence the findings of the study or their interpretations.
    3. Impede the patient's ability to complete the entire duration of the study.
  6. History of anaphylaxis to any biologic therapy.
  7. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the investigator may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete the entire duration of the study.
  8. Any clinically significant cardiac disease or any (ECG) abnormality obtained during the screening period, which in the opinion of the investigator may put the patient at risk or interfere with study assessments.
  9. Positive surface antigen, or virus antibody serology, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without history of hepatitis B are allowed to enrol.
  10. A helminth parasitic infection diagnosed within 24 weeks prior to the date of and assent is obtained that has not been treated with, or has failed to respond to, standard of care therapy.
  11. or aspartate aminotransferase level ≥ 1.5 times the confirmed during the screening period.
  12. A history of known immunodeficiency disorder including a positive (HIV) test.
  13. Use of medication, including, but not limited to, methotrexate, troleandomycin, cyclosporine, azathioprine, intramuscular long-acting depot , or any experimental anti-inflammatory therapy, within 3 months prior to Visit 1. Chronic maintenance corticosteroid for the treatment of asthma is allowed.
  14. Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.
  15. Receipt of any marketed (eg, Omalizumab, Mepolizumab, or off-label Benralizumab) or biologic within 4 months or 5 half-lives, whichever is longer, prior to Visit 1.
  16. Receipt of 30 days prior to the date of first dose of IP.
  17. Initiation of new allergen immunotherapy is not allowed within 30 days prior to Visit 1. However, allergen immunotherapy initiated prior to this period can be continued provided there is a gap of 7 days between the immunotherapy and IP administration.
  18. Current use of any oral or ophthalmic non-selective β-adrenergic antagonist (eg, propranolol).
  19. Planned surgical procedures during the conduct of the study.
  20. Participation in another clinical study with an investigational nonbiologic product administered in the last 30 days or 5 half-lives prior to enrolment, whichever is longer.
  21. Known history of allergy or reaction to any component of the IP formulation.
  22. Concurrent enrolment in another clinical study.
  23. Parent/guardian has a history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (eg, inability to read, comprehend and write) which will limit the validity of consent to participate in this study.
  24. Unwillingness or inability of the participant or parent/guardian to follow the procedures outlined in the protocol.
  25. Children who are wards of the state or government.
  26. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  27. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  28. Previous treatment in the present study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Dose 1

    Below 35 kilos

    Drug: Benralizumab

  • Experimental
    Dose 2

    Greater than/equal to 35 kilos

    Drug: Benralizumab

Interventions

  • Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.

06

What researchers measure

Primary outcomes

  1. Clearance of Benralizumab

    Blood samples were collected to determine the clearance of benralizumab. This was an empirical Bayesian estimate (EBE) derived posthoc using population PK analysis.

    Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

  2. Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab

    Blood samples were collected to determine the AUC0-28 of benralizumab and it was calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Pre-dose on Days 0, 28 and post-dose on Days 1, 7, 14

  3. Maximum Observed Serum Concentration (Cmax) of Benralizumab

    Blood samples were collected to determine Cmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

  4. Terminal Phase Elimination Half-Life (t1/2) of Benralizumab

    Blood samples were collected to determine the t1/2 of benralizumab and it was calculated as natural logarithm of 2 \[ln(2)\]/terminal rate constant (λZ). This was an EBE derived posthoc using population PK analysis.

    Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

  5. Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab

    Blood samples were collected to determine the tmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

  6. Trough Concentration of Benralizumab at Week 16 (Ctrough16)

    Blood samples were collected to determine the trough concentration at Week 16, the lowest concentration reached by benralizumab before the next dose was administered. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Pre-dose on Day 112

  7. Change From Baseline in Peripheral Blood Eosinophil Count up to Week 48

    Blood samples were collected for determination of eosinophil count levels and were assessed in a central laboratory. Baseline is the last non-missing measurement prior to the first dose of study treatment.

    Time frame: Baseline (Day 0) and at Weeks 4, 8, 12, 16, 24 and 48

Secondary outcomes

  1. Body Weight-Adjusted Clearance of Benralizumab

    Blood samples were collected to determine the clearance of benralizumab. This was an EBE derived posthoc using population PK analysis.

    Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

  2. Number of Participants With Anti-Drug Antibodies (ADA) Response to Benralizumab

    Blood samples were analyzed for the presence of ADAs for benralizumab. ADA prevalence: ADA positive (+ve) at any time point including baseline and/or post baseline. Treatment induced ADA+ve: ADA negative (-ve) at baseline and post-baseline ADA+ve. Treatment-boosted ADA+ve: baseline +ve ADA titer that was boosted by \>4-fold or higher-level following study drug administration. Treatment-emergent ADA+ve: either treatment-induced ADA+ve or treatment-boosted ADA+ve. Persistently +ve ADA: having at least 2 post-baseline ADA+ve assessments with at least 16 weeks (112 days) between the first and last +ve assessments, or an ADA+ve result at the last available assessment. Transiently +ve ADA: having at least 1 post-baseline ADA+ve assessment(s) and not persistently ADA+ve. Neutralizing antibodies (nAb) prevalence: nAb+ve at baseline and/or post-baseline. Treatment-induced nAb+ve (nAb incidence): nAb-ve at baseline (or ADA-ve at baseline) and nAb+ve at any post-baseline visit.

    Time frame: Pre-dose at Baseline (Day 0), Weeks 8, 16 and 24 and post-dose at Week 48; and at early discontinuation or withdrawal visit

  3. Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) up to Week 48

    The FEV1 was defined as the volume of air exhaled from the lungs in the first second of a forced expiration and was measured by spirometry. Baseline is the last non-missing measurement with acceptable quality prior to the first dose of study treatment.

    Time frame: Baseline (Day 0) and at Weeks 16 and 48

  4. Change From Baseline in Interviewer-Administered Asthma Control Questionnaire (ACQ-IA) Score up to Week 48

    The ACQ-IA is a 6-item assessment comprised of 6 patient-reported items. Participants were asked to record their experience with 5 symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, and wheezing) and use of short-acting beta-2 agonist (SABA) over the previous week using a 7-point scale (0 = no impairment; and 6 = maximum impairment). The ACQ-IA score was calculated by the mean of the 7 equally weighted items. The score ranged from 0 (well controlled) to 6 (extremely poorly controlled). Higher scores indicated poor asthma control. Baseline is the last non-missing measurement prior to the first dose of study treatment.

    Time frame: Baseline (Day 0), at Weeks 16 and 48; and at early discontinuation or withdrawal visit

  5. Number of Responders in Interviewer-Administered Patient Global Impression of Change (PGIC)-IA and Clinician Global Impression of Change (CGIC) Questionnaires

    The PGIC-IA and CGIC instruments were used for an overall evaluation of response to treatment, conducted separately by the Investigator and by the participant (administered by trained individuals to help the child understand the question and response options), using a 7-point scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; and 7=very much worse. The Investigator (clinician) and the participant were asked to rate the degree of change in the overall asthma status compared to the start of study treatment visit. Participants were defined as responders based on categorized responses for PGIC-IA and CGIC. Responder status categories included Improved=Very much improved, Much improved, Minimally improved, Much improved=Much improved, Very much improved, Very much improved=Very much improved. CGIC = PGIC-IA indicates agreement between CGIC and PGIC-IA assessments of response to treatment at the same visit.

    Time frame: At Weeks 16 and 48; and at early discontinuation or withdrawal visit

07

Results

Posted May 18, 2023

Participant flow

This Phase III, open-label, parallel group study was conducted in pediatric participants with severe eosinophilic asthma at 17 investigational sites in the United States and Japan between 21 Nov 2019 and 12 Sep 2022.

Participant flow — Overall Study
MilestoneBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
Started1515
Completed1514
Not completed01
Withdrew: Withdrawal by parent/guardian01

Outcome measures

PrimaryClearance of Benralizumab

Blood samples were collected to determine the clearance of benralizumab. This was an empirical Bayesian estimate (EBE) derived posthoc using population PK analysis.

Time frame:
Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Reported as:
Mean · liter (L) per day
Clearance of Benralizumab
liter (L) per dayAll Participants
Clearance of Benralizumab0.156 ± 0.0598
PrimaryArea Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab

Blood samples were collected to determine the AUC0-28 of benralizumab and it was calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Pre-dose on Days 0, 28 and post-dose on Days 1, 7, 14
Reported as:
Geometric mean · nanogram*day per milliliter (ng*day/mL)
Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab
nanogram*day per milliliter (ng*day/mL)Benralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab36918.01 ± 24.6175593.37 ± 39.9636918.01 ± 24.6173670.51 ± 38.86
PrimaryMaximum Observed Serum Concentration (Cmax) of Benralizumab

Blood samples were collected to determine Cmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Reported as:
Geometric mean · ng/mL
Maximum Observed Serum Concentration (Cmax) of Benralizumab
ng/mLBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
Maximum Observed Serum Concentration (Cmax) of Benralizumab1901.18 ± 28.423118.69 ± 47.351901.18 ± 28.423090.85 ± 43.66
PrimaryTerminal Phase Elimination Half-Life (t1/2) of Benralizumab

Blood samples were collected to determine the t1/2 of benralizumab and it was calculated as natural logarithm of 2 \[ln(2)\]/terminal rate constant (λZ). This was an EBE derived posthoc using population PK analysis.

Time frame:
Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Reported as:
Median · day
Terminal Phase Elimination Half-Life (t1/2) of Benralizumab
dayAll Participants
Terminal Phase Elimination Half-Life (t1/2) of Benralizumab14.4 (6.94 to 23.4)
PrimaryTime to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab

Blood samples were collected to determine the tmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Reported as:
Median · day
Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab
dayBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab6.91 (0.93 to 14.95)7.26 (1.10 to 14.01)6.91 (0.93 to 14.95)7.94 (1.10 to 14.01)
PrimaryTrough Concentration of Benralizumab at Week 16 (Ctrough16)

Blood samples were collected to determine the trough concentration at Week 16, the lowest concentration reached by benralizumab before the next dose was administered. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Pre-dose on Day 112
Reported as:
Geometric mean · ng/mL
Trough Concentration of Benralizumab at Week 16 (Ctrough16)
ng/mLBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
Trough Concentration of Benralizumab at Week 16 (Ctrough16)142.42 ± 256.34339.35 ± 409.24142.42 ± 256.34340.46 ± 363.69
PrimaryChange From Baseline in Peripheral Blood Eosinophil Count up to Week 48

Blood samples were collected for determination of eosinophil count levels and were assessed in a central laboratory. Baseline is the last non-missing measurement prior to the first dose of study treatment.

Time frame:
Baseline (Day 0) and at Weeks 4, 8, 12, 16, 24 and 48
Reported as:
Mean · cells/microliters
Change From Baseline in Peripheral Blood Eosinophil Count up to Week 48
cells/microlitersBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
Week 4-447.3 ± 283.76-436.9 ± 408.28-447.3 ± 283.76-455.3 ± 385.58
Week 8-445.3 ± 276.20-453.8 ± 396.03-445.3 ± 276.20-470.7 ± 374.25
Week 12-443.3 ± 286.85-455.8 ± 419.32-443.3 ± 286.85-472.9 ± 393.49
Week 16-446.7 ± 279.12-402.7 ± 384.61-446.7 ± 279.12-430.0 ± 378.68
Week 24-354.2 ± 323.99-436.9 ± 405.90-354.2 ± 323.99-457.9 ± 397.77
Week 48-434.0 ± 286.15-453.8 ± 392.78-434.0 ± 286.15-474.3 ± 385.04
SecondaryBody Weight-Adjusted Clearance of Benralizumab

Blood samples were collected to determine the clearance of benralizumab. This was an EBE derived posthoc using population PK analysis.

Time frame:
Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Reported as:
Mean · L/day/kilogram
Body Weight-Adjusted Clearance of Benralizumab
L/day/kilogramAll Participants
Body Weight-Adjusted Clearance of Benralizumab0.00408 ± 0.000764
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA) Response to Benralizumab

Blood samples were analyzed for the presence of ADAs for benralizumab. ADA prevalence: ADA positive (+ve) at any time point including baseline and/or post baseline. Treatment induced ADA+ve: ADA negative (-ve) at baseline and post-baseline ADA+ve. Treatment-boosted ADA+ve: baseline +ve ADA titer that was boosted by \>4-fold or higher-level following study drug administration. Treatment-emergent ADA+ve: either treatment-induced ADA+ve or treatment-boosted ADA+ve. Persistently +ve ADA: having at least 2 post-baseline ADA+ve assessments with at least 16 weeks (112 days) between the first and last +ve assessments, or an ADA+ve result at the last available assessment. Transiently +ve ADA: having at least 1 post-baseline ADA+ve assessment(s) and not persistently ADA+ve. Neutralizing antibodies (nAb) prevalence: nAb+ve at baseline and/or post-baseline. Treatment-induced nAb+ve (nAb incidence): nAb-ve at baseline (or ADA-ve at baseline) and nAb+ve at any post-baseline visit.

Time frame:
Pre-dose at Baseline (Day 0), Weeks 8, 16 and 24 and post-dose at Week 48; and at early discontinuation or withdrawal visit
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA) Response to Benralizumab
ParticipantsBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
ADA prevalence3131
Treatment-emergent ADA+ve3131
Post-baseline ADA+ve3131
Baseline and at least 1 post-baseline ADA+ve0000
Only baseline ADA+ve0000
Persistently ADA+ve1010
Transiently ADA+ve2121
nAb prevalence3131
nAb incidence3131
SecondaryChange From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) up to Week 48

The FEV1 was defined as the volume of air exhaled from the lungs in the first second of a forced expiration and was measured by spirometry. Baseline is the last non-missing measurement with acceptable quality prior to the first dose of study treatment.

Time frame:
Baseline (Day 0) and at Weeks 16 and 48
Reported as:
Mean · liters
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) up to Week 48
litersBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
Week 16-0.001 ± 0.2434-0.119 ± 0.2435-0.001 ± 0.2434-0.165 ± 0.2609
Week 480.003 ± 0.34120.425 ± 0.43950.003 ± 0.34120.428 ± 0.4209
SecondaryChange From Baseline in Interviewer-Administered Asthma Control Questionnaire (ACQ-IA) Score up to Week 48

The ACQ-IA is a 6-item assessment comprised of 6 patient-reported items. Participants were asked to record their experience with 5 symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, and wheezing) and use of short-acting beta-2 agonist (SABA) over the previous week using a 7-point scale (0 = no impairment; and 6 = maximum impairment). The ACQ-IA score was calculated by the mean of the 7 equally weighted items. The score ranged from 0 (well controlled) to 6 (extremely poorly controlled). Higher scores indicated poor asthma control. Baseline is the last non-missing measurement prior to the first dose of study treatment.

Time frame:
Baseline (Day 0), at Weeks 16 and 48; and at early discontinuation or withdrawal visit
Reported as:
Mean · scores on a scale
Change From Baseline in Interviewer-Administered Asthma Control Questionnaire (ACQ-IA) Score up to Week 48
scores on a scaleBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
Week 16-0.62 ± 0.890-1.18 ± 1.717-0.62 ± 0.890-1.06 ± 1.696
Week 48-0.56 ± 1.252-1.36 ± 1.369-0.56 ± 1.252-1.31 ± 1.324
SecondaryNumber of Responders in Interviewer-Administered Patient Global Impression of Change (PGIC)-IA and Clinician Global Impression of Change (CGIC) Questionnaires

The PGIC-IA and CGIC instruments were used for an overall evaluation of response to treatment, conducted separately by the Investigator and by the participant (administered by trained individuals to help the child understand the question and response options), using a 7-point scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; and 7=very much worse. The Investigator (clinician) and the participant were asked to rate the degree of change in the overall asthma status compared to the start of study treatment visit. Participants were defined as responders based on categorized responses for PGIC-IA and CGIC. Responder status categories included Improved=Very much improved, Much improved, Minimally improved, Much improved=Much improved, Very much improved, Very much improved=Very much improved. CGIC = PGIC-IA indicates agreement between CGIC and PGIC-IA assessments of response to treatment at the same visit.

Time frame:
At Weeks 16 and 48; and at early discontinuation or withdrawal visit
Reported as:
Count of participants · Participants
Number of Responders in Interviewer-Administered Patient Global Impression of Change (PGIC)-IA and Clinician Global Impression of Change (CGIC) Questionnaires
ParticipantsBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
PGIC-IA, Week 16, improved13121313
PGIC-IA, Week 16, much improved10101011
PGIC-IA, Week 16, very much improved4849
PGIC-IA, Week 48, improved13121313
PGIC-IA, Week 48, much improved910911
PGIC-IA, Week 48, very much improved99910
CGIC, Week 16, improved13111312
CGIC, Week 16, much improved8989
CGIC, Week 16, very much improved3535
CGIC, Week 48, improved15131514
CGIC, Week 48, much improved811812
CGIC, Week 48, very much improved5656
CGIC = PGIC-IA, Week 16, improved106106
CGIC = PGIC-IA, Week 16, much improved7575
CGIC = PGIC-IA, Week 16, very much improved3434
CGIC = PGIC-IA, Week 48, improved9898
CGIC = PGIC-IA, Week 48, much improved5757
CGIC = PGIC-IA, Week 48, very much improved5656

Adverse events

Collected over Treatment-emergent adverse events were collected from the start of study drug administration (Day 1) until end of follow-up, approximately up to Week 53. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab Dose 1, Aged 6-11 Years0/15 (0%)1/15 (6.7%)13/15 (86.7%)
Benralizumab Dose 2, Aged 6-11 Years0/13 (0%)2/13 (15.4%)9/13 (69.2%)
Benralizumab Dose 1, Aged 6-14 Years0/15 (0%)1/15 (6.7%)13/15 (86.7%)
Benralizumab Dose 2, Aged 6-14 Years0/15 (0%)4/15 (26.7%)11/15 (73.3%)
Most frequent serious events
Most frequent serious events
EventBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
AsthmaRespiratory, thoracic and mediastinal disorders1/152/131/154/15
Somatic symptom disorderPsychiatric disorders0/150/130/151/15
Most frequent other events
Showing 10 of 56
Most frequent other events
EventBenralizumab Dose 1, Aged 6-11 YearsBenralizumab Dose 2, Aged 6-11 YearsBenralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 Years
NasopharyngitisInfections and infestations4/151/134/152/15
CoughRespiratory, thoracic and mediastinal disorders0/153/130/153/15
PyrexiaGeneral disorders3/151/133/151/15
COVID-19Infections and infestations1/152/131/152/15
Viral upper respiratory tract infectionInfections and infestations2/152/132/152/15
VomitingGastrointestinal disorders2/150/132/150/15
PneumoniaInfections and infestations0/151/130/152/15
SinusitisInfections and infestations2/150/132/150/15
Pain in extremityMusculoskeletal and connective tissue disorders2/150/132/150/15
HeadacheNervous system disorders2/151/132/151/15

Baseline characteristics

The Safety Analysis set consisted of all participants who received at least 1 dose of benralizumab.

Age, Continuous
Age, Continuous(years)Benralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 YearsTotal
Mean8.3 ± 2.029.8 ± 1.939.0 ± 2.09
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 YearsTotal
Female4711
Male11819
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 YearsTotal
White448
Black or African American358
Asian8311
American Indian or Alaska Native000
Native Hawaiian or other Pacific Islander000
Other033
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benralizumab Dose 1, Aged 6-14 YearsBenralizumab Dose 2, Aged 6-14 YearsTotal
Hispanic or Latino156
Not Hispanic or Latino141024
08

Study locations

15 sites
  • Research Site
    Los Angeles, California 90078, United States
  • Research Site
    Orlando, Florida 32827, United States
  • Research Site
    Lincoln, Nebraska 68505, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Coppell, Texas 75019, United States
  • Research Site
    San Antonio, Texas 78251, United States
  • Research Site
    Fukuoka-shi, 811-1394, Japan
  • Research Site
    Fukuoka-shi, 813-0017, Japan
  • Research Site
    Fukuyama-shi, 721-8511, Japan
  • Research Site
    Gifu-shi, 500-8717, Japan
  • Research Site
    Habikino-shi, 583-8588, Japan
  • Research Site
    Saga-shi, 840-8571, Japan
  • Research Site
    Tsu-shi, 514-0125, Japan
  • Research Site
    Zentsuji-shi, 765-8507, Japan
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Sep 2022, 33 months.

Results were first posted in May 2023, 8 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 33 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2019
First posted
Mar 12, 2020
StartActual
Nov 21, 2019
Primary completionActual
Sep 12, 2022
CompletionActual
Sep 12, 2022
Results first posted
May 18, 2023
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04305405
Lead sponsor
AstraZeneca
Collaborators
Iqvia Pty Ltd, Parexel, Covance, PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Mar 12, 2020
Start date
Nov 21, 2019
Primary completion
Sep 12, 2022
Completion
Sep 12, 2022
Results posted
May 18, 2023
Last update
May 18, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion